Lantheus touts Pylarify PET agent results at AUA meeting

Lantheus Medical Imaging is directing attention to research presented at the recent 2021 American Urological Association (AUA) virtual annual meeting involving its Pylarify PET radiopharmaceutical (piflufolastat F-18).

The researchers examined the utility of the prostate specific membrane antigen-targeted tracer during initial assessment on men with high-risk prostate cancer. After receiving a piflufolastat F-18 scan, 72 of 268 men in the trial were found to have regional lymph node and/or distant metastases that were radiographically staged as N1/M0 (39 patients) or as N0/M1 or N1/M1 disease (33 patients), according to the vendor.

In addition, Lantheus presented an independent, retrospective review on the impact of piflufolastat F-18 imaging on patient management in the trial. The vendor found that incorporating piflufolastat F-18 imaging led to a potential change in planned management for 43.6% (115/264) of patients. In 39% (103/264), a change in surgery or type of surgery was recommended and in 25.8% (68/264), a change in planned radiation therapy was recommended.